目的 比较全面地介绍国内外生物制药生产的新近发展状况,讨论生物制药发展中几个值得注意的动向。方法 根据本实验室的研究与调研及国内外有关文献资料,对生物制药产业在国民经济和现代医药工业中的地位以及国内外生物制药产业的持续快速发展状况作了归纳分析。同时讨论影响我国生物制药产业发展的值得关注的几个动向。结果与结论 进入21世纪以来,生物制药产业持续高速发展已是现代制药工业的主导产业,它为提升“生物经济”在国民经济中的地位起着重要作用。发展具有知识产权的生物制药产业,突破动物细胞表达治疗蛋白与大规模培养技术工程化是我国发展现代生物制药产业的关键;非专利生物药物与生物制药受托生产(CMO)也是值得专注的发展方向。
关键词
生物制药 /
生物技术药物 /
非专利生物药物 /
生物制药受托生产 /
治疗性抗体 /
疫苗 /
重组治疗蛋白
{{custom_keyword}} /
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] WANG Y T,WU W T,WU W J. An overriew and features of development of Chinese biopharmaceutical biotechnology[J]. Pharm Biotechnol(药物生物技术),2010,17(1):1-14.
[2] SANG G W. Facing the financial crisis: the pharmaceutical industry derelopment and drug innovation in China[J]. Chin Pharm J(中国药学杂志), 2010, 45(1):1-4.
[3] HU X W,CHEN H P,ZHANG S R. A view of biopharmaceutical enterprises in the world[J]. Chin Med Biotechnol(中国医药生物技术),2009,4(2):85-89.
[4] ZHANG T M,SONG A Z,WANG F S. Advance of biochemical drugs research in China[J]. Chin Pharm J(中国药学杂志),2009,44(20):1512-1525.
[5] IBIS World industry report,Biotechnology in US,NN001[R]. March,11,2009.
[6] Ch.P(2010)(中国药典2010年版)[S].2010.
[7] RUAN L. Advance of virus vaccines research in China[J]. Biotechnology & Business(生物产业技术),2009,(3):26-37.
[8] YU J R,CHEN D M,JIANG H B. The trend of research in China[J]. Biotechnology & Business (生物产业技术),2009(1):49-53.
[9] Gary Walsh & Roy Jecfferis,Post-translational modifications in the context of ther Gpeutic proteins[J]. Nat Biotechnol,2006,24(10):1241-1250.
[10] WU J,MA Q J. Advance on research of the long effects of protion drugs[J]. Biotechnology & Business(生物产业技术),2009,(3):46-51.
[11] FARE F,GANEM S,HAJOUJ T, et al. Development of a long-atring erythropoietin by fusing the carboxyl-terminal peopticle of human chorionic gonadotropin betasubunite to the coding sequence of human erythropoietrin[J].Endocrinology,2007,148(10):5081-5087.
[12] HUANG B R. The future of research and development on polypeptides(proteins), drugs in neurotic system[J]. Biotechnology & Business(生物产业技术),2009,(3):52-63.
[13] LI Y P,LI Z R. Research development of polypeptide antibacteriol aqents[J]. World Notes Antibiot(国外医药:抗生素分册). 2010,30(4):148-153.
[14] ZHU J,GAO X,YI Y .Advance of research on antibacterial peptides[J]. Chin Bull Life Sci(生命科学),2008,20(4):606.
[15] WANG D X,LIN H,YANG P X, et al. Structure modification of peptides: The rational way for drug development [J] .Chin New Drugs J (中国新药杂志),2007,16(20):1646-1650.
[16] HANMEI X,CHANG L Z,HENG Z, et al. Progress in the veseach of therapeutic enzymt[J].Chin J Biotechnol(生物工程学报),2010,25(12):1852-1862.
[17] CHEN C S,ZHAO Q,WANG J, et al. Enhanced anti-tumor effects achieved in a murine tumor model using combination therapy of recombinunt human manganese superoxide dismutase and adriarmycin. Biochem [J].Biophys Res Commun,2008,370(4):663-668.
[18] WHITEHEAD K A,LANGER R,ANDERSON D G. Knocking down barriers:advances in siRNA delivery[J]. Nat Rev Drug Discov,2009,8(6):129-138.
[19] CASTANOTTO D,ROSS J J. The promises and pitfalls of RNA interference-based therapeutics[J]. Nature,2009,457(22):426-433.
[20] WURDINGER T,COSTA F F. Molecular theapy in the micro RNA era[J]. Pharmacogenomics Journal,2007,7(5):297-304.
[21] RUBIN L L. Stem cell and drug discovery[J]. Cell,2008,132(4):549-552.
[22] GUNNESS B A,MULHERKAR R. Internatinal progress in cancer gene theraing[J]. Cancer Gene Ther,2008,15(12):765-775.
[23] HEYE X J. The trend of evelopment on follow on biologics[J]. Biotechnology & Business(生物产业技术),2010,(1):23-26.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}